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Abstract Mild Cognitive Impairment (MCI) is a disease between normal cognitive ageing and 
dementia. In recent years the term MCI has been recognized as a pre-dementia state, raising an 
important subject for investigation in the prevention of dementia. There are various terms 
related to pre-dementia MCI, such as isolated memory complaint and pre-Alzheimer’s disease; 
most of them do not comprise all the areas related to MCI. A central cholinergic deficit is 
present in amnestic MCI with neuronal loss in the Meynert basal nucleus. It is estimated that the 
rate of progression to dementia is about 10% every year. The prevalence of MCI is 10%-11% and 
the risk of progression to dementia is about 5%-16%. The continual development of pharmacologic 
approaches to modify and delay the natural history of progression of the disease motivates a 
great interest in an earlier diagnosis.
1665-5796 © 2014 Revista Medicina Universitaria. Facultad de Medicina UANL. Publicado por Elsevier México. Todos 
los derechos reservados.
Introduction 
Mild cognitive impairment (MCI) is an intermediate mental 
state between a normal cognitive state and dementia. In 
recent years, MCI has been recognized as a pre-dementia 
state, becoming an important subject for investigation in 
the prevention of dementia. There are several terms rela-
ted to pre-dementia MCI, such as isolated memory com-
plaint and pre-Alzheimer disease (AD); most of them do not 
comprise all the area related to MCI.1 MCI is a heteroge-
neous pathology in terms of clinical presentation, etiology, 
prognosis and prevalence; however, there is still controver-
sy in its deinition. Some studies have demonstrated that 
MCI can be reversed to a normal cognitive state. Prevalence 
is 3-19% in the elderly population, with an incidence bet-
ween 8 to 58 per 1,000 people a year and a risk of develo-
ping into dementia of 11-33% within 2 years.2 Memory 
disorders represent a public health issue, with an average of 
4.5 years until a patient is diagnosed with dementia, with 
major disabilities and economic loss for the family and the 
health sector.3,4 In Mexico there is no information about pa-
tients’ survival. 
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Mild cognitive impairment subgroups
Amnestic MCI
It is considered to be AD’s main predecessor; it is the most 
common subgroup with a 2:1 ratio compared with non-am-
nestic MCI. There are 2 classiications within this subgroup: 
single non-memory domain MCI and multi-domain MCI. The 
former refers to individuals who have a signiicant memory 
deicit (classiied by the result of a battery of neuropsycho-
logical tests) but do not meet the criteria for a dementia 
diagnosis; criteria for this classiication are: presence of a 
cognitive complaint (conirmed by an informant), impaired 
memory determined objectively (correlated with age and 
educational level, and represented by an impairment grea-
ter than 1.5 standard deviations [SD] from the normal para-
meter), preserved general cognitive functions, the fact that 
everyday activities remain normal, and not meeting criteria 
for a dementia diagnosis. Amnestic multi-domain MCI inclu-
des those people who do not manifest a cognitive decline 
greater than 0.5-1 SD for their age and educational level. 
We have followed up on these patients and they generally 
do not display an evolution towards vascular dementia or 
AD.5
Within this MCI subgroup, the cognitive proile relects 
normal aging; prognostic usefulness of this MCI is not clear. 
There is controversy among the different studies regarding 
this subgroup’s conversion to dementia or the return to a 
normal cognitive state.6
Non-amnestic MCI 
This type of MCI is characterized by an isolated impairment in 
a single non-memory domain, for instance an impairment of 
the executive function, language, or visuospatial skills. The 
non-amnestic MCI-single domain subgroup will progress, de-
pending on the affected domain, to fronto-temporal 
dementia, primary progressive aphasia, Lewy body demen-
tia, progressive supranuclear palsy, or corticobasal degene-
ration. Individuals in this group are considered to have a 
lower risk of conversion to dementia; however, evidence 
supporting this theory is limited.  In regard to the non-am-
nestic multiple domains MCI subtype, it is considered that 
one of the main disorders is the development of neuroi-
brillary plaques caused by the proteins tau and alfa-synu-
clein.7 
Epidemiology
There is a great variation between the reported prevalence 
rates, luctuating between 2% and 20% in different series. 
Studies which have used different measurements such as 
age-related cognitive decline, cognitive impairment, no de-
mentia, and minimal dementia estimate prevalence bet-
ween 16% and 22% in adults older than 60. In several 
cohort-type studies, incidences between 14 and 77 for every 
1,000 patients older than 60 years have been reported. Ma-
les have an odds ratio of 1:5 in community studies of pa-
tients between 70 and 89 years.2 The National Health and 
Aging Study in Mexico (ENASEM by its Spanish acronym) as-
sessed the prevalence of cognitive impairment and its rela-
tionship with sociodemographic factors in the population, 
inding that just 7% had cognitive impairment and 3.3% had 
cognitive impairment and functional dependency.3 
Pathology 
Regarding histopathological indings, and MCI being a clinical 
expression of early symptoms of dementia, researchers detec-
ted intermediate indings between normality and advanced 
dementia. A central cholinergic deicit is present in amnestic 
MCI, related to neuronal loss in the basal nucleus of Meynert.8 
In postmortem studies, evidence of a positive regulation in 
the acetyl transferase activity in the frontal cortex and hippo-
campus has been found.9 There is evidence that cerebrovascu-
lar and neurodegenerative conditions contribute to MCI, 
especially white matter lesions and small lacunar infarcts.10
One of the main problems in the diagnosis of MCI is deter-
mining how much the memory processes are affected. Some 
criteria establish that in order to reach a diagnosis of MCI, 
the patient’s performance carrying out memory tasks must 
be inferior to the average obtained by normal adults; howe-
ver, other criteria establish that for a diagnosis of MCI, pa-
tients must be compared with subjects of the same age and 
educational level.
A very important point in the subgroup of patients with 
diabetes mellitus is to recognize that there is an exacerba-
ted neurotoxicity caused by the beta amyloid plaques se-
condary to the advanced glycation end-products in their 
matrix; moreover, in animal models the existence of a dimi-
nished cholinergic transporter in patients with cognitive im-
pairment and diabetes has been found4 (Fig. 1).
Hypertension has been studied as a risk factor for cogniti-
ve impairment because it affects cerebral vasculature 
through different mechanisms, including strokes, leu-
koaraiosis, atherosclerosis, etc.
In transversal studies, it has not been possible to ind an 
evident association with arterial hypertension as a risk fac-
tor while in longitudinal studies such association has been 
demonstrated. Dyslipidemia has also been studied in diffe-
rent population samples inding a correlation between MCI 
and hyperlipidemia (especially hypercholesterolemia) 
in middle-aged patients. Furthermore, we are able to see in 
different studies that there is a protective association bet-
ween the use of statins and MCI. Other risk factors which 
have been analyzed include chronic renal failure, vitamin 
B12 deiciency, vitamin D deiciency, hyperhomocysteine-
mia, testosterone deiciency, subclinical hypothyroidism, 
smoking, and excessive alcohol consumption.
Population studies
Many authors and institutions (The World Health Organi-
zation and The American Academy of Neurology, among 
others) have supported the term MCI.  In recent years they 
have been trying to establish a greater delimitation of the 
term, mainly because different types of mild cognitive im-
pairments have arisen (amnestic, non-amnestic, aphasia, 
apraxia or agnostic).
Most of the studies are directed at evaluating MCI, and 
are focused, mainly, in observing the performance in the 
memory processes in older people, considering there is 
well-founded evidence showing that cognitive complaints 
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have a high prevalence in this population, suggesting a pre-
clinical phase of a process of dementia; even though there 
are many longitudinal cohort studies of non-demented sub-
jects, who have been developing cognitive impairment.
One of the most representative investigations about MCI, 
and one which has been taken as a reference, was carried 
out by the researchers at Mayo Clinic in the United States. 
The objective of the researchers was to clinically classify 
subjects with MCI through a transversal and longitudinal stu-
dy. A sample of 76 subjects with MCI was compared to 234 
control subjects and with 106 patients with mild AD from 
the clinic or from the community register of patients with 
AD in Rochester. All 3 groups were evaluated longitudinally 
using instruments which evaluate cognitive performance 
(MMSE, WAIS-R, WMS-R, Dementia Rating Scale, Free and 
Cued Selective Reminding Test and Rey’s Auditory Verbal 
Learning Test, among others). Mild AD diagnosis was esta-
blished by the DSM-III-R and the NINCDS-ADRDA. The results 
showed that in general intelligence measurements, subjects 
with MCI performance were more similar to that from con-
trol subjects than from patients with mild AD. In particular, 
in the complete WAIS-R scale, control subjects obtained an 
average IQ = 101.8 and subjects with MCI obtained an avera-
ge IQ = 98, while patients with mild AD obtained an average 
IQ = 83.9. The results with the MMSE were very similar; con-
trol and MCI subjects obtained an average score of 28.3 and 
26 respectively, while patients with mild AD obtained an 
average score of 22.6. On the other hand, subjects with MCI 
obtained a lower result than control subjects in the Contro-
lled Oral Word Association Test, even though these results 
were within the normal expected range for their age, based 
on the community studies used for this research. However, 
performance carrying out memory tasks was very similar in 
subjects with MCI and patients with mild AD, yet the decli-
ning range of subjects with MCI performing these kinds of 
tasks was lower to the one showed by patients with mild AD 
but higher than that in control subjects. Researchers came 
to the conclusion that subjects considered under MCI crite-
ria may be differentiated both from control subjects and 
patients with mild AD, thus considering MCI as a clinical en-
tity characterized by a group of symptoms and amenable to 
of pharmacologically interactive treatment.5
Another study with great signiicance in MCI research was 
one carried out in St. Luis Missouri, US, where the local el-
derly population volunteered. The sample was of 454 sub-
jects, who were classified according to the CDR as 
“cognitively healthy” (n = 177 y CDR = 0) and Lewy body 
dementia (LBD) (n = 277 and CDR = 0.5).
Based on the clinical suspicion that MCI represents an 
early stage of Alzheimer’s, the MCI group with a score on the 
CDR = 0.5 was subdivided into three subgroups. The study 
had a follow-up of 9-and-a-half years, evaluating subjects 
with a neuropsychological battery and a neuropathological 
test for the subjects who passed away during research. 
The objective was to observe the progression of sub- 
jects towards a score in the CDR = 1, which characterizes 
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Figure 1 Histopathologic changes in the brain and its clinical correlation.
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“deinite” mild Alzheimer’s. The evaluation protocol inclu-
ded items from brief standardized cognitive assessment bat-
teries, such as MMSE and the Short Blessed Test (Katzman 
et al. 1983), among others. In general, the results showed 
that all the subjects with CDR = 0-5 displayed memory im-
pairment and a higher frequency of alelo e4 of the gene 
apoe compared to normal subjects CDR = 0. The second cog-
nitive domain frequently more impaired was the judgment 
and problem solving skill. On the other hand, the results 
showed that 100% of the subjects of the group CDR=5- 
Alzheimer’s progress to a severe dementia in a period of 9.5 
years, of the rate of conversion of this group to Alzheimer’s 
in 5 years 60.5% with an equal or superior score to 1 in the 
CDR. In the CDR = 0.5- incipient Alzheimer’s, the range 
of conversion to Alzheimer’s in 5 years was 35.7% and, for 
the CDR = 0.5- uncertain dementia, its range of conversion 
in the same period of time was 19.9%; However, in the con-
trol subjects (CDR = 0), the conversion range was only 6.8%. 
The conclusion was that MCI generally represents an early 
stage of Alzheimer’s, due to the fact that progression to a 
severe dementia correlates with the base line of the degree 
of impairment, in other words, 96% of the subjects with CDR 
= 0.5 progressed to a neuropathological state of dementia, 
and out of these, 84% were an Alzheimer-type dementia1
In a different study, Ritchie et al, with the objective of 
evaluating the predictive validity and temporal stability 
of the diagnosis criteria of MCI, analyzed a sample of 833 
subjects with subclinical cognitive impairments, taken from 
a previous longitudinal study called the Eugeria Project, ca-
rried out in Montpellier, in the south of France. The sample 
was representative of the population and covered urban as 
well as rural populations. The study followed the cohort 
of subjects during a period of 3 years.  During the irst year, 
subjects were evaluated with an instrument used to screen 
cognitive functioning denominated Détérioration Cognitive 
Observée (DECO), which has demonstrated in diverse stu-
dies its high sensitivity to detect early changes in cognitive 
functioning due to different causes, observing the degree of 
change during the last year. Its estimation is similar to the 
one of a close person who has had continuous monthly con-
tact with the patient during a period of three years. Using a 
neuropsychological computerized exam which covers most 
of the cognitive functions, six cognitive domains were selec-
ted; attention, primary memory, secondary memory, visuo-
spacial skills, language and reasoning. In a second phase, 
MCI subjects were classiied. The results showed that MCI 
prevalence in the general population was approximately 
3.2%, and of cognitive impairment adjusted to their age of 
19.3%. Thus, MCI turned out to be a poor background to 
a preclinical dementia phase in a period of three years, with 
a risk of conversion of 11.1% constituting, in general, an 
unstable group, because most of the subjects who belonged 
to this group, experimented category switches every year. 
On the contrary, the cognitive impairment adjusted group 
proved to be more homogenous and stable, with a conver-
sion rate to dementia of 28.6% in a period of 3 years. The 
researchers came to the conclusion that criteria for MCI pro-
vide a poor performance when applied to a representative 
sample, given the fact that in most of the investigations 
which proposes MCI as a clinical diagnostic entity, samples 
have been obtained out of small selected clinical groups. 
Because cognitive complaints in older adults are the main 
symptom to establish MCI criteria, several clinical studies 
have been carried out. These studies have tried to establish 
the predictive power of cognitive complaints in the memory 
processes.6 Furthermore, it is important to emphasize “The 
Canadian Study of Health and Aging” for its importance in 
which they carried out a 5-year follow-up of 10,263 elder-
lies (over 65 years and up), representing the general popu-
lation of older adults (residents of the community, as well 
as institutionalized).  In this epidemiologic study about 
health care, dementia and functional state the term “no-
dementia cognitive impairment” surfaces, which represents 
a cognitive disorder accompanied by a mild neuro-cognitive 
disorder, also, it is attributable to a subjacent functional di- 
sorder.  In this study they obtained results which indicate 
that non-dementia cognitive impairment prevalence is 
16.8% in people older than 64 years.  From this study on, 
several parallel studies utilized samples from this study7 
(Fig. 2).
Clinical assessment
The corner stone of diagnosis consists of a detailed clinical 
interview, ideally with the presence of an informant. There 
are several scale systems, since 1982 there have been 2 
main ones which are used to this day: Clinical Dementia Ra-
ting (CDR) which gives a point system of 0 for normal 
people, 1 for mild dementia, and 0.5 for mild cognitive de-
terioration, and The Global Deterioration Scale (GDS) which 
scores mild cognitive deterioration with a score of 3 where 
patients display cognitive deicits and suffer alterations in 
the executive function which affects social and occupatio-
nal activities. It is important to keep in mind that the scales 
do not mean 100% MCI diagnosis, because it is necessary to 
check it with the clinical indings, and medical history. In 
order to evaluate the subjects’ cognitive proile using the 
Folstein Mini-Mental State Examination Tool (MMSE), or via 
Montreal Cognitive Assessment (MOCA) taking into account 
their respective sensitivity and speciicity. A medical and 
neurological examination must be carried out in order to 
identify non-degenerative cognitive alterations causes8,9 
(Fig. 3).
Emphasizing MMSE is one of the most utilized tests to eva-
luate these cognoscitive symptoms, it is very important to 
remember that this test assesses memory, orientation, lan-
guage, spatial skills, attention, and calculus. It takes about 
10 minutes to apply. Its score ranges from 0 to 30. A cut-off 
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Figure 2 Dementia spectrum.
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point of 23 is generally recommended as an indicator of 
cognitive impairment. The test has a reliability of 0.89. One 
of its limitations is the fact that it is inluenced by several 
factors; for example, the level of education. Some authors 
even consider the test to be affected by the patient’s ability 
to read. Other authors believe the test is affected by demo-
graphic factors such as gender and age. Therefore, differen-
tial cut-off points between subgroups have been suggested 
and alternative items have been generated (Galasko: the 
months of the year backwards).
There are certain considerations which must be taken into 
account for MCI diagnosis:
1. An international working group has formulated spe-
cific recommendations in MCI criteria: The indi- 
vidual is not demented nor its in the normal cate-
gory. There should be evidence of impairment in 
cognition, demonstrated by a decline in time, or 
subjective reports made by an informant. Everyday 
activities are preserved and complex functions are 
intact or minimally affected.10 
2. It has been noted that neuropsychiatric symptoms 
including dysphoria, irritability, hallucinations, 
apathy, depression, agitation, and delusions are 
more frequent in MCI and Alzheimer dementia pa-
tients. The presence of neuropsychiatric symptoms 
involves a greater risk for MCI patients of progres-
sing into AD. The Neuropsychiatric Inventory (Cum-
mings et al., 1994) is the most used scale to assess 
neuropsychiatric alterations including 12 areas (agi- 
tation, delusion, hallucinations, depression, eu-
phoria, abnormal motor activity, apathy, irritabili-
ty, disinhibition, anxiety, drowsiness and hunger); a 
patient’s relative who may have the information is 
questioned about these symptoms.11 
3. Psychiatric conditions (depression), medication ad-
verse events (anticholinergics, antihistamines), 
sleep disorders, infections, metabolic diseases (vi-
tamin B12 deiciency, hypothyroidism, hyperglyce-
mia, hypoglycemia, uremia, hepatopathy, sodium 
disorders), structural brain diseases.11 Due to a 
great diversity of pathologies, researchers have 
tried to ind ideal biomarkers for a more accura- 
te diagnosis; we must remember that markers may 
be positive in non-demented subjects. Some of 
these markers reflect key cognitive impairment 
processes in the cerebrospinal luid, such as the le-
vels of isoform of beta 42 amyloid and Tau protein. 
Other studied markers include amyloid deposits or 
neuroibrillary plaques like Pittsburgh B compound 
or the 18-FDDNP.12 There are other markers which 
relect secondary processes like neuron dysfunction 
or neuronal loss either by electroencephalogram 
(EEG), nuclear magnetic resonance or positron 
emission tomography scan. As far as EEG goes, re-
searchers have found that the rate between theta 
and alpha 1 waves is a reliable individual rate of 
cerebrovascular damage.13
4. Cerebral biopsy plays a very limited role in the 
diagnosis of dementia; its diagnostic capabilities 
are minimal, the procedure is invasive and invol- 
ves risk for major complications. The biopsy is re-
served for younger patients and for those with aty-
pical clinical presentations with potentially 
treatable causes.
It is very important to promote the recognition and ack-
nowledgement of this pathology as several studies have 
shown that between 29% and 76% of the cases may be iden-
tiied in irst contact care.14 Studies show that patients with 
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Figure 3 Clinical classiication and cause of MCI.
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MCI display a wide range of malnutrition. A study by The 
European Society for Clinical Nutrition and Metabolism 
found that from a sample of 623 patients, 18% had a normal 
nutrition status, 58% were at risk of malnutrition, and 24% 
showed clear malnutrition; thus, we must keep in mind that 
these types of patients display more alterations within the 
corporal economy in addition to neurological deiciencies.15 
Within a pragmatic approach in the study of MCI, it is of 
great importance to cite several key questions for a proper 
assessment16 (Fig. 4):
1. What is the patient’s basal functional status?
2. How is the symptomatology’s evolution? (regarding 
time of onset)
3. What is the main characteristic of this deficit? 
(short-term or long term memory)
4. Are there any changes in behavior?
5. Is there a co-existence of depression in this pa-
tient?
6. Could the patient in question have a serious subcli-
nical pathology?
Neuroimaging
Neuroimaging use is controversial; most guides do not re-
commend routine imaging studies, but they include rules to 
help identify patients who may have reversible causes of 
dementia, with factors that include being under 60 years 
old, showing focal neurological signs, and having been 
affected less than 2 years from the onset of the disease. 
However, their sensitivity and speciicity are low. Magnetic 
resonance imaging (MRI) indings include focal and generali-
zed atrophy, as well as white matter lesions; in general, 
these are unspeciied indings. A tomography is important 
in those patients with acute unsaturation of the cognosciti-
ve impairment and rapid neurological deterioration.17
A longitudinal cohort study was carried out in Rotterdam, 
The Netherlands. The main objective of this study was to 
determine whether or not the hippocampus and amygdala 
volume measured by MRI were useful for predicting the de-
velopment of dementia in older people without cognitive 
impairment. The investigators monitored 511 patients bet-
ween 60 and 90 years of age, for an average period of 6 
years. Over this period of time, the atrophy of the hippo-
campus and the amygdala measured by MRI predicted a 
time of development of dementia of 6 years, with a risk rate 
adjusted to age, gender, and educational level of 3 (95% 
conidence interval [CI] 2.0-4.6) for every unit of standard 
deviation for the hippocampus and of 2.1 (95% CI 1.5-2.9) 
for the amygdalin level. In patients with cerebral atrophy 
and leukoaraisis, the exact correlation degree and inluence 
between imaging findings and the results of the neurop-
sychological tests are unknown. Therefore, it is hard to clas-
sify this type of patient, because there are cases with major 
pathological indings and imaging representing a preserved 
cognition.18
Transcranial Doppler ultrasound
Imaging techniques to analyze cerebral circulation are very 
diverse, there is no such thing as the ideal study. Transcra-
nial Doppler ultrasound is a test performed with a portable 
device which allows measuring several blood low parame-
ters as well as the Circle of Willis, providing information 
about the velocity of blood low (cm/s) through the brain’s 
blood vessels, resistance rates, and pulsatility, as well as 
the brain’s vasoreactivity following stimuli such as hyper-
ventilation, induced hypercapnia, and even medications 
like acetazolamide. This study is performed with the pa-
tient in a decubitus position, after resting for 10 minutes, at 
room temperature, and comfortable, with the head at a 30 
degree angle in a semi-Fowler position; a basal register is 
recorded and blood pressure registered every 5 minutes 
during the inhalation of 5%-7% carbon dioxide (CO2) for 5 
minutes with an aesthetic mask covering both mouth and 
nose. The most utilized protocol is to register the velocity 
of systolic and diastolic low, as well as the average resting 
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low of the middle cerebral artery and then again 5 minutes 
after inhaling CO2, assessing the responsive ability of cere-
bral arteries on entrance of carbon dioxide, numbers that 
adjust to age, gender, and changes in blood pressure. In pa-
tients with hypertension, after the vasodilator stimulus the-
re is a decrease in the cerebral microvascular reactivity 
(explained by the decrease in the dilation ability to the va-
sodilator stimulus), which can be improved through the ad-
ministration of antihypertensive medications.19 
It has been shown that cerebral blood low and cerebral 
vasoreactivity gradually decrease with age, and that this 
decrease is directly related to the presence of cerebral mi-
cro-strokes and impairment of cognitive function; in addi-
tion, vasoreactivity of the occipital is diminished even more 
in vascular dementia which is statistically signiicant com-
pared to AD.20
Progression to dementia
The risk of dementia progression is estimated to be 10% per 
year; as for MCI patients, yearly progression rates luctuate 
between 5% and 16%. Several long-term studies (over 5 
years) have found that the risk of conversion decreases with 
time. Some of the factors associated with an increased risk 
of progression to dementia are socioeconomic variables and 
age while gender and level of education are not considered 
as factors. Age constitutes the main predictor of progres-
sion, risk increasing exponentially for every year people get 
older. The apolipoprotein E-epsilon4 (APOe4) genotype has 
been associated with an increased risk, as well as raised le-
vels of the protein Thr phosphorylated tau 181, low levels of 
amyloid beta 42, rise in the activity of the beta-secretase, 
and of neprilysin (a degrading enzyme beta-amyloid pepti-
de) activity diminution. An important rate of reversion of 
MCI to a normal cognitive state is observed (20%-25%).21
The American Academy of Neurology’s evidence–based 
guidelines for early detection states that MCI patients 
should be detected early and followed long-term, because 
of their high risk of subsequent development of dementia.2 
For dementia detection in individuals suspected of cog-
noscitive impairment, screening instruments used to assess 
progression are: Mini-Mental State Examination (score of 
224 or less, speciicity 57%-99%, sensitivity 82%-99%, positi-
ve predictive value 68%-91%, negative predictive value 96%-
99%, evidence class I and II, the percentages vary because 
of the risk of dementia in each population, age classiica-
tion, etc.), Kokmen short test of mental state (speciicity 
88%, sensitivity 86%), 7-minute screen, memory impairment 
screen (speciicity 96%, sensitivity 87%, positive predictive 
value 54%-85%), Clock drawing test (speciicity 96%, sensibi-
lity 92%), and Blessed dementia rating scale (specificity 
46%, sensitivity 94%).
Moreover, different instruments should be applied for di-
fferent aspects of the cognoscitive function, being more 
useful the ones which emphasize memory, for example the 
Mattis dementia rating scale (mainly focused on attention, 
initiative, perseverance, building, memory, and conceptua-
lization, between 129/144, sensitivity 98%, speciicity 97%). 
It is necessary to apply neuropsychological batteries on 
the risk population, like the IQCODE  (Informant Question-
naire on Cognitive Decline in the Elderly) or the CDR which 
is a scale with 6 categories, and is based in orientation, 
judgment, memory, personal care, performance within the 
house and hobbies, with a score of over 1, a speciicity of 
94% was demonstrated and a sensitivity of 92%.
Diabetic patients have an odds ratio of 1.2-1.5 to obtain 
lower scores than those who are non-diabetics, regarding 
cognitive function; measured by Mini-Mental and the digital 
symbol test.22 
An adequate conversion to dementia prediction must be 
made on those patients with mild cognitive impairment al-
ready established, there are several models; one of the 
most important is the “Five-Predictor Combination” with a 
sensitivity of 85.2% and 90% speciicity based on age, Mini-
Mental result, “Selective Reminding Test”, Functional acti-
vities questionnaire and University of Pennsylvania smell 
identiication test23 (Fig. 5).
Importance of the subject
The constant emergence of pharmacological and non-phar-
macological preventive treatments to slow down or modify 
the course in AD and the other types of dementia, boost a 
great interest of reaching an early diagnosis in order to start 
acting as soon as possible with these patients. MCI is an ade-
quate state for new therapies, thus its differential diagnosis 
is crucial, and a thing that nowadays is controversial, with 
great debates regarding its delimitation and acceptance as 
a new diagnostic entity. The development of speciic instru-
ments for MCI diagnosis is one of the most urgent tasks, gi-
ven the fact that the current instruments have a signiicant 
tendency to only detect risk factors. Different studies agree 
that an adherence to the Mediterranean-style diet (hazard 
ratio [HR] = 0.60, CI 0.42-0.87) and high physical activity 
(HR = 0.67, CI 0.47-0.95) are independently associated with 
a reduced risk of cognitive impairment.24 Knowledge of an 
adequate control of systemic hypertension reduces the risk 
of developing vascular dementia, dementia with Lewy bo-
dies, and frontotemporal dementia; nevertheless, it does 
not significantly decrease the development of MCI (RR = 
0.97, CI 0.92-1.03) or AD.25 Currently, there is little eviden-
ce of the effectiveness and speciicity of interventions that 
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improve memory in the healthy elderly and those with MCI; 
studies show that after a systemic training the results impro-
ved in immediate and delayed verbal memory. Information 
to recommend MCI screening in asymptomatic individuals is 
lacking. Therefore, there is ongoing research and population 
analysis in order to determine which subjects will beneit 
the most from the search of this pathology.26 
Treatment
Adherence to a Mediterranean-style diet has been margina-
lly associated with the reduction of progression of MCI to AD 
(HR = 0.55, 95% CI 0.34-0.9).27
According to the Cochrane Collaboration, there are no 
studies assessing the role that carbohydrates play in impro-
ving the performance of the evaluation in older people with 
MCI.28 
High-intensity aerobic exercise may be beneicial for pa-
tients with MCI; results of studies carried out with small ran-
domized samples to exercise 40 to 60 minutes 4 days a week 
for a period of 6 months, have shown that exercise impro-
ved the levels of the factor similar to the growth hormone, 
plasma insulin reduction when fasting, cortisol, and execu-
tive function.29
Cholinesterase inhibitors slow down the conversion to full 
dementia for up to 3 years, but it has been associated with 
adverse effects in adults with MCI (diarrhea, nausea, vomi-
ting, cramps, insomnia, headaches, syncope or vertigo); the 
most studied are donepezil, galantamine, and rivastigmine, 
the relative risks of progression to dementia are 0.69 (95% 
CI 0.47-1) within 1 year, 0.67 (95% CI 0.55-0.83) within 2 
years, and 0.84 (95% CI 0.7-1.02) within 3 years.30which is 
frequently updated from the major healthcare databases 
(MEDLINE, EMBASE, CINAHL, PsycINFO and Lilacs
Galantamine is not recommended because of the mortali-
ty risk increase, with a number needed to harm (NNH) of 
100;31 in addition, it has not really been associated with a 
diminution in the progression to dementia.32
In regards to donepezil, it may slow down the progression 
of AD; this is based on randomized studies of patients who 
received this medication at 5 mg a day for 6 weeks, which 
was titrated to 10 mg a day for 3 years. In general, the pro-
gression to dementia was seen in 16% of the 769 patients, 
with a significant improvement at 6, 12 and 24 months; 
among patients who were carriers of APOe4, the improve-
ment in executive function was notable up to 3 years of fo-
llow-up.33 The most common adverse effects were diarrhea 
(NNH 10), cramps (NNH 7), insomnia (NNH 11), nausea 
(8.4%), vomiting (6%), and arthritis (2.5%).34 
There are other diverse therapies for which the net clini-
cal benefit provided is unknown; these include nicotine 
patch,35 gingko biloba,36 vitamin E,11 vitamins B6
37 and B12,
38 
folic acid,39 procaine,40 piracetam,41 and huperzine A.42
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